An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the long-term safety of CB-03-01 cream,
1% applied twice daily for an additional nine months in study participants with acne vulgaris
that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.